Novartis is eyeing an FDA filing for a second drug in immunoglobulin A nephropathy (IgAN), as the Swiss pharma goes all-in on the rare autoimmune kidney disease from three different angles.
Use of the drug semaglutide in patients with type 2 diabetes significantly reduced the risk of major kidney disease events, cardiovascular outcomes and all-cause mortality vs. placebo, newly published data show.“These benefits signify a profound clinical impact saving kidneys, hearts and lives for patients with type 2 diabetes and chronic kidney disease,” Vlado Perkovic, MB, PS, PhD,